Intra-nasal ketamine — Competitive Intelligence Brief

Intra-nasal ketamine (Intra-nasal ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Psychiatry, Pain Management, Anesthesia.

marketed NMDA receptor antagonist NMDA receptor Psychiatry, Pain Management, Anesthesia Small molecule

Target snapshot

Intra-nasal ketamine (Intra-nasal ketamine) — Lions Gate Hospital. Intranasal ketamine is a non-competitive NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce dissociative and analgesic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intra-nasal ketamine TARGET	Intra-nasal ketamine	Lions Gate Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
ketamine and propofol	ketamine and propofol	Ain Shams University	marketed	Intravenous anesthetic combination	NMDA receptor (ketamine); GABA-A receptor (propofol)
Ketamine + methadone	Ketamine + methadone	Cedars-Sinai Medical Center	marketed	NMDA receptor antagonist + synthetic opioid agonist combination	NMDA receptor (ketamine); mu opioid receptor (methadone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

1. Turku University Hospital · 3 drugs in this class
2. H. Lundbeck A/S · 2 drugs in this class
3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
4. Shalvata Mental Health Center · 2 drugs in this class
5. New York State Psychiatric Institute · 2 drugs in this class
6. Auris Medical AG · 1 drug in this class
7. AstraZeneca · 1 drug in this class
8. Alameda Health System · 1 drug in this class
9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
10. Asker & Baerum Hospital · 1 drug in this class